In such a context, a very recent study has demonstrated that levels of CXCL10 and CXCL11, two C-X-C chemokines exerting angiostatic effects through their receptor CXCR3-B [49], are strongly increased in the circulation of SSc patients from the earliest disease stages, and may represent good biomarkers of vascular damage progression [50]. This evidence concerns the gene CXCL11 and systemic sclerosis.